These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. New insights into the pathogenesis, diagnosis, and management of mastocytosis. Fuller SJ Hematol Oncol Clin North Am; 2012 Dec; 26(6):1143-68. PubMed ID: 23116574 [TBL] [Abstract][Full Text] [Related]
4. Mastocytosis: from a Molecular Point of View. Komi DEA; Rambasek T; Wöhrl S Clin Rev Allergy Immunol; 2018 Jun; 54(3):397-411. PubMed ID: 28725969 [TBL] [Abstract][Full Text] [Related]
5. Mastocytosis: state of the art. Horny HP; Sotlar K; Valent P Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883 [TBL] [Abstract][Full Text] [Related]
7. Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease. Gülen T; Hägglund H; Dahlén B; Nilsson G J Intern Med; 2016 Mar; 279(3):211-28. PubMed ID: 26347286 [TBL] [Abstract][Full Text] [Related]
8. [Mastocytosis--diagnostic criteria and treatment]. Dereń-Wagemann I; Kuliszkiewicz-Janus M; Kuliczkowski K Postepy Hig Med Dosw (Online); 2009 Nov; 63():564-76. PubMed ID: 20009120 [TBL] [Abstract][Full Text] [Related]
9. Mastocytosis: current concepts in diagnosis and treatment. Escribano L; Akin C; Castells M; Orfao A; Metcalfe DD Ann Hematol; 2002 Dec; 81(12):677-90. PubMed ID: 12483363 [TBL] [Abstract][Full Text] [Related]
10. [Guidelines for the diagnosis, treatment and management of mastocytosis]. De la Hoz B; González de Olano D; Alvarez I; Sánchez L; Núñez R; Sánchez I; Escribano L An Sist Sanit Navar; 2008; 31(1):11-32. PubMed ID: 18496577 [TBL] [Abstract][Full Text] [Related]
11. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. Valent P; Sperr WR; Schwartz LB; Horny HP J Allergy Clin Immunol; 2004 Jul; 114(1):3-11; quiz 12. PubMed ID: 15241337 [TBL] [Abstract][Full Text] [Related]
13. New Insights into Clonal Mast Cell Disorders Including Mastocytosis. Volertas S; Schuler CF; Akin C Immunol Allergy Clin North Am; 2018 Aug; 38(3):341-350. PubMed ID: 30007455 [TBL] [Abstract][Full Text] [Related]
14. Update on Mastocytosis (Part 2): Categories, Prognosis, and Treatment. Azaña JM; Torrelo A; Matito A Actas Dermosifiliogr; 2016; 107(1):15-22. PubMed ID: 26525106 [TBL] [Abstract][Full Text] [Related]
15. Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. Arock M; Akin C; Hermine O; Valent P Eur J Haematol; 2015 Jun; 94(6):474-90. PubMed ID: 25753531 [TBL] [Abstract][Full Text] [Related]
18. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Pardanani A Blood; 2013 Apr; 121(16):3085-94. PubMed ID: 23426950 [TBL] [Abstract][Full Text] [Related]
19. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL. Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351 [TBL] [Abstract][Full Text] [Related]
20. [Mastocytosis: advances in molecular diagnosis and therapeutics]. Arock M Ann Pharm Fr; 2004 Jul; 62(4):233-43. PubMed ID: 15243341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]